Press Release

J.P. Morgan Life Sciences Private Capital Hires Joseph Siletto to Target Investments in Healthcare Transformation

Mr. Siletto joins from Vivo Capital as Co-Managing Partner

New York, NY – July 11, 2024 J.P. Morgan Private Capital, a venture and growth equity investment team within J.P. Morgan Asset Management Alternatives, today announced its next phase of growth with the hiring of industry veteran Joseph Siletto as a new Managing Partner alongside Anya Schiess and Gaurav Gupta, M.D., M.S.E, reporting to Stephen Squinto, Ph.D. The expanded team will look to invest in Series B through pre-IPO stage healthcare companies, specifically within the biotechnology, medical devices, health technology and services, and diagnostics and tools subsectors.

“I’m delighted to join the globally esteemed team at J.P. Morgan Life Sciences Private Capital,” said Joseph Siletto, Managing Partner, J.P. Morgan Life Sciences Private Capital. “As part of a world-class investment team, I’m looking forward to leveraging J.P. Morgan’s existing presence in the healthcare sector that we believe will give us a significant sourcing advantage as we seek to identify innovative and transformative healthcare companies.”

Based in Boston, Mr. Siletto has over 25 years of experience investing in the private healthcare space and most recently was Managing Director at Vivo Capital. Prior to this role, he co-founded Scion Medical Technologies.

The expanded platform will look to finance opportunities that aim to enhance disease treatment and patient outcomes while reducing costs through several key initiatives, including but not limited to: supporting innovative treatment methods, utilizing cutting-edge technology, applying increased computing power with artificial intelligence to develop more impactful treatments, improving diagnostic tools for earlier disease detection and prevention, and delivering healthcare solutions to patients in a more cost effective way.

“As advances in biotechnology and artificial intelligence continue to transform the healthcare industry, our expanded team should allow us to take advantage of this transition, and remain a preferred partner for companies looking to implement innovative ways to treat, identify and prevent disease,” said Anya Schiess, Managing Partner, J.P. Morgan Life Sciences Private Capital

Biography

Joseph Siletto is Co-Managing Partner of Life Sciences Private Capital (“LSPC”) within J.P. Morgan Private Capital, a division of J.P. Morgan Global Alternatives in J.P. Morgan Asset Management. Joseph joined from Vivo Capital in 2024. While at Vivo, Joseph focused on sourcing investments, executing transactions and serving on the board of directors for growth and private equity companies. Over his time with the firm, he sourced and served on the board of over 10 companies. In addition to his investment and board responsibilities, Joseph also took an active operations role within several portfolio companies. Prior to his time at Vivo, Joseph created the business plan and was the co-founder for Scion Medical Technologies, a company which completed a half dozen acquisitions to build a global, commercial medical device portfolio focused on interventional oncology. Scion was ultimately sold to NYSE-listed Varian Medial and is now part of Siemens. Prior to his time as an entrepreneur and investor, Joseph was an investment banker for Cowen & Company and Bank of America Securities focused on healthcare M&A and capital raising. Joseph has a Bachelor of Arts from Duke University and an MBA from the Haas School of Business at the University of California at Berkeley.

About J.P. Morgan Private Capital

J.P. Morgan Private Capital provides customized financing solutions for private companies across the capital structure with a focus on venture and growth investing. The platform’s solutions span the consumer, technology, and life sciences sectors.

J.P. Morgan Private Capital is part of J.P. Morgan Global Alternatives, the alternative investment arm of J.P. Morgan Asset Management. With over 60 years of experience in managing alternative investments, $214 billion in assets under management and over 800 professionals (as of March 31, 2024), its strategies cover the full spectrum of alternatives: real estate, private equity, private credit, liquid alternative products, infrastructure, transport, hedge funds and forestry. From the Americas, Europe and Asia, independent alternative investment teams combine their cutting-edge expertise with J.P. Morgan's resources, infrastructure and global reach to achieve each client's specific objectives. For more information : jpmorgan.com/am

About J.P. Morgan Asset Management

J.P. Morgan Asset Management, with assets under management of $3.2 trillion (as of 3/31/2024), is a global leader in investment management. J.P. Morgan Asset Management's clients include institutions, retail investors and high net worth individuals in every major market throughout the world. J.P. Morgan Asset Management offers global investment management in equities, fixed income, real estate, hedge funds, private equity and liquidity. For more information: . J.P. Morgan Asset Management is the marketing name for the asset management businesses of JPMorgan Chase & Co., and its affiliates worldwide.

JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America (“U.S.”), with operations worldwide. JPMorgan Chase had $4.1 trillion in assets and $337 billion in stockholders’ equity as of March 31, 2024. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. Under the J.P. Morgan and Chase brands, the Firm serves millions of customers in the U.S., and many of the world’s most prominent corporate, institutional and government clients globally. Information about JPMorgan Chase & Co. is available at .

J.P. Morgan Life Sciences team members' past investing and operating experience is provided solely in order to illustrate the nature of their professional experience with respect to the types of investments and transactions that JPM intends to pursue and is not indicative of JPM's future results and should not be understood as JPM's “track record” information or be relied upon in connection with any investment or other related decision.

9ee4eaae-3d68-11ef-bace-f5029f0df385

Copyright 2025 JPMorgan Chase & Co. All rights reserved.

This website is a general communication being provided for informational purposes only. It is educational in nature and not designed to be a recommendation for any specific investment product, strategy, plan feature or other purposes. By receiving this communication you agree with the intended purpose described above. Any examples used in this material are generic, hypothetical and for illustration purposes only. None of J.P. Morgan Asset Management, its affiliates or representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. Communications such as this are not impartial and are provided in connection with the advertising and marketing of products and services. Prior to making any investment or financial decisions, an investor should seek individualized advice from personal financial, legal, tax and other professionals that take into account all of the particular facts and circumstances of an investor's own situation.

 

Opinions and statements of financial market trends that are based on current market conditions constitute our judgment and are subject to change without notice. We believe the information provided here is reliable but should not be assumed to be accurate or complete. The views and strategies described may not be suitable for all investors.

 

INFORMATION REGARDING INVESTMENT ADVISORY SERVICES: J.P. Morgan Asset Management is the brand for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide. Investment Advisory Services provided by J.P. Morgan Investment Management Inc.

 

INFORMATION REGARDING MUTUAL FUNDS/ETF: Investors should carefully consider the investment objectives and risks as well as charges and expenses of a mutual fund or ETF before investing. The summary and full prospectuses contain this and other information about the mutual fund or ETF and should be read carefully before investing. To obtain a prospectus for Mutual Funds: Contact JPMorgan Distribution Services, Inc. at 1-800-480-4111 or download it from this site. Exchange Traded Funds: Call 1-844-4JPM-ETF or download it from this site.

 

J.P. Morgan Funds and J.P. Morgan ETFs are distributed by JPMorgan Distribution Services, Inc., which is an affiliate of JPMorgan Chase & Co. Affiliates of JPMorgan Chase & Co. receive fees for providing various services to the funds. JPMorgan Distribution Services, Inc. is a member of FINRA FINRA's BrokerCheck

 

INFORMATION REGARDING COMMINGLED FUNDS: For additional information regarding the Commingled Pension Trust Funds of JPMorgan Chase Bank, N.A., please contact your J.P. Morgan Asset Management representative.

 

The Commingled Pension Trust Funds of JPMorgan Chase Bank N.A. are collective trust funds established and maintained by JPMorgan Chase Bank, N.A. under a declaration of trust. The funds are not required to file a prospectus or registration statement with the SEC, and accordingly, neither is available. The funds are available only to certain qualified retirement plans and governmental plans and is not offered to the general public. Units of the funds are not bank deposits and are not insured or guaranteed by any bank, government entity, the FDIC or any other type of deposit insurance. You should carefully consider the investment objectives, risk, charges, and expenses of the fund before investing.

 

INFORMATION FOR ALL SITE USERS: J.P. Morgan Asset Management is the brand name for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide.

 

NOT FDIC INSURED | NO BANK GUARANTEE | MAY LOSE VALUE

 

Telephone calls and electronic communications may be monitored and/or recorded.

 

Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our privacy policies at https://www.jpmorgan.com/privacy.

 

If you are a person with a disability and need additional support in viewing the material, please call us at 1-800-343-1113 for assistance.

 

READ IMPORTANT LEGAL INFORMATION. CLICK HERE >

 

The value of investments may go down as well as up and investors may not get back the full amount invested.

 

Diversification does not guarantee investment returns and does not eliminate the risk of loss.